Published in Health and Medicine Week, March 13th, 2006
The patent is entitled "Peptide-based Multimeric Targeted Contrast Agents." As issued, its term extends through July 30, 2022. The patent covers EP-2104R, EPIX's investigational fibrin-binding imaging agent, which is completing phase IIa clinical studies.
The company also announced that it has...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health and Medicine Week